Image: Guerbet showcased its ongoing and future innovations at ECR 2022 (Photo courtesy of Guerbet)
Guerbet (Paris, France) introduced new innovations bringing the future of MRI into focus and offered real-time clinical demonstrations at the on-site European Congress of Radiology (ECR) held in Vienna on July 13-17. The ECR is the annual meeting of the European Society of Radiology (ESR), which represents more than 125,000 members worldwide. The ECR is one of the largest medical congresses in the world, attracting more than 30,000 congress participants. With 300 companies exhibiting across more than 26,000m², its exhibition is also one of the largest medical exhibitions in Europe.
At ECR 2022, Guerbet demonstrated the Contrast&Care Contrast Dose Management Solution which is a class I /CE medical device designed to be used by healthcare professionals only. The contrast product injection management solution enables imaging centers to collect, archive, examine and share injection data, including data on contrast products, adverse events, injector activity, information on estimated glomerular filtration rate (eGFR) and other risk factors before an exam. Guerbet also demonstrated the OptiVantage Multi-Use injector which is an optimal power injector that enables fast and comfortable changes between patients in addition to save time and money and being user-friendly. Guerbet also demonstrated in real-time how the Contrast&Care Contrast Dose management solution and OptiVantage Multi-Use injector can be fully interconnected for enhanced benefits to users.
Guerbet demonstrated the OptiStar Elite MR Contrast Delivery System, a simple, reliable MRI contrast media injector that incorporates advanced performance features, thus reducing operating costs and improving patient throughput. In addition, visitors to the company’s ECR booth were given a demonstration of Icobrain software which is designed to help radiologists and neurologists diagnose and monitor patients with neurological disorders. The artificial intelligence software extracts clinically meaningful information from brain CT or MRIs scans of patients with multiple sclerosis, dementia or brain injury. Icobrain can be used to automate the currently manual process of identifying, marking and quantifying volumes of brain structures identified.